MedTrace Logo

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

NCT05420922 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-06-15

No results posted yet for this study

Summary

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.

Conditions

Interventions

DRUG

Lenvatinib Oral Product

Lenvatinib or Sorafenib

DRUG

PD-1 inhibitor

Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1

PROCEDURE

Local treatment

Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Xiaoping Chen, Doctor · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-08-30
Completion
2022-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05420922 on ClinicalTrials.gov